Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 1
1966 1
1972 1
1976 4
1977 2
1980 1
1983 2
1984 1
1986 1
1987 4
1988 11
1989 1
1990 1
1993 2
1994 4
1995 5
1996 3
1997 5
1998 6
1999 6
2000 5
2001 11
2002 2
2003 5
2004 2
2005 7
2006 11
2007 11
2008 9
2009 11
2010 19
2011 18
2012 30
2013 32
2014 34
2015 40
2016 45
2017 44
2018 54
2019 63
2020 77
2021 90
2022 85
2023 85
2024 67
2025 69

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

881 results

Results by year

Filters applied: . Clear all
Page 1
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R. Gradishar WJ, et al. Among authors: soliman h. J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. doi: 10.6004/jnccn.2024.0035. J Natl Compr Canc Netw. 2024. PMID: 39019058
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar R. Gradishar WJ, et al. Among authors: soliman h. J Natl Compr Canc Netw. 2023 Jun;21(6):594-608. doi: 10.6004/jnccn.2023.0031. J Natl Compr Canc Netw. 2023. PMID: 37308117
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R. Gradishar WJ, et al. Among authors: soliman h. J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. doi: 10.6004/jnccn.2022.0030. J Natl Compr Canc Netw. 2022. PMID: 35714673
CXCR6 orchestrates brain CD8+ T cell residency and limits mouse Alzheimer's disease pathology.
Su W, Saravia J, Risch I, Rankin S, Guy C, Chapman NM, Shi H, Sun Y, Kc A, Li W, Huang H, Lim SA, Hu H, Wang Y, Liu D, Jiao Y, Chen PC, Soliman H, Yan KK, Zhang J, Vogel P, Liu X, Serrano GE, Beach TG, Yu J, Peng J, Chi H. Su W, et al. Among authors: soliman h. Nat Immunol. 2023 Oct;24(10):1735-1747. doi: 10.1038/s41590-023-01604-z. Epub 2023 Sep 7. Nat Immunol. 2023. PMID: 37679549 Free PMC article.
The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake.
de Mingo Pulido Á, Hänggi K, Celias DP, Gardner A, Li J, Batista-Bittencourt B, Mohamed E, Trillo-Tinoco J, Osunmakinde O, Peña R, Onimus A, Kaisho T, Kaufmann J, McEachern K, Soliman H, Luca VC, Rodriguez PC, Yu X, Ruffell B. de Mingo Pulido Á, et al. Among authors: soliman h. Immunity. 2021 Jun 8;54(6):1154-1167.e7. doi: 10.1016/j.immuni.2021.04.019. Epub 2021 May 11. Immunity. 2021. PMID: 33979578 Free PMC article.
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S, Jansen VM, Litchfield LM, Sledge GW. Tolaney SM, et al. Among authors: soliman h. Clin Cancer Res. 2022 Apr 14;28(8):1500-1506. doi: 10.1158/1078-0432.CCR-21-3276. Clin Cancer Res. 2022. PMID: 35121623 Free PMC article. Clinical Trial.
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto WA, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, An Y, Chiang V, Nakano T, Aoyama H, Mehta MP. Sperduto PW, et al. Among authors: soliman h. J Clin Oncol. 2020 Nov 10;38(32):3773-3784. doi: 10.1200/JCO.20.01255. Epub 2020 Sep 15. J Clin Oncol. 2020. PMID: 32931399 Free PMC article.
Which Way to (INDI)GO?
Udovicich C, Soliman H. Udovicich C, et al. Among authors: soliman h. Int J Radiat Oncol Biol Phys. 2025 Jun 1;122(2):220. doi: 10.1016/j.ijrobp.2024.12.047. Int J Radiat Oncol Biol Phys. 2025. PMID: 40382159 No abstract available.
Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy.
Patin EC, Nenclares P, Chan Wah Hak C, Dillon MT, Patrikeev A, McLaughlin M, Grove L, Foo S, Soliman H, Barata JP, Marsden J, Baldock H, Gkantalis J, Roulstone V, Kyula J, Burley A, Hubbard L, Pedersen M, Smith SA, Clancy-Thompson E, Melcher AA, Ono M, Rullan A, Harrington KJ. Patin EC, et al. Among authors: soliman h. Nat Commun. 2024 Aug 13;15(1):6923. doi: 10.1038/s41467-024-51236-6. Nat Commun. 2024. PMID: 39134540 Free PMC article.
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.
O'Connell BC, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok JL, Varner J, Ilaria R Jr, Cobleigh MA, Juric D, Tkaczuk KHR, Elias A, Lee A, Dakhil S, Hamilton E, Soliman H, Peluso S. O'Connell BC, et al. Among authors: soliman h. J Immunother Cancer. 2024 Aug 30;12(8):e009160. doi: 10.1136/jitc-2024-009160. J Immunother Cancer. 2024. PMID: 39214650 Free PMC article. Clinical Trial.
881 results